This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
23 Feb 2016

Launch of Valid Insight provides support for market access

Valid Insight’s launch aims to meet the market access challenges facing new medicines, helping life science research to translate into real-world benefits for patients and society.

Dr Steve Bradshaw, leading a team of key life science advisors and industry experts, has launched Valid Insight, a new market access consultancy created to help drug developers navigate the challenges of market access for new and innovative therapeutics.

Getting new medicines and health technologies to patients who need better treatment is becoming increasingly testing, and payers and health technology assessment bodies are demanding growing levels of evidence to show real-world value.

Valid Insight’s advisors have decades of specialist experience and business knowledge in market access, health economics, outcomes research, and product and health technology launch, pricing and reimbursement. They understand the complexity of the life science landscape and the challenges and hurdles faced by manufacturers, payers, prescribers and patients in demonstrating real-world value.

“We are investing considerable resources in developing our expertise, methods and offerings, including real-world evidence, that help our clients optimize the commercial success of their products,” said Dr Bradshaw, Valid Insight founder and managing director. “I believe that the launch of Valid Insight, and the experts we have on board, will help our clients to build the global landscape of tomorrow’s healthcare environment and deliver better outcomes to patients and society.”

The Valid Insight team will put its expertise to work to provide integrated and strategic research, analysis and value communication solutions to create insight into the market and clinical opportunity, develop evidence, communicate value and build and support centres of excellence through education and training. Its core services are based on its wealth of real in-house expertise and on primary and secondary research, including real-world evidence and research with key opinion leaders and payers.

Related News